Recent Updates
Recently added Catalysts

KITE-363

Phase 1

Systemic Lupus Erythematosus | Monoclonal antibody | Immunology |Gilead Sciences, Inc.|Last Updated: Jul 1, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
CONTROLLEDDMC
Total Trials1
Total Enrollment52
FDA Designations
No designations recorded
Clinical trial landscape

KITE-363 · 3 trials · 8 indications

Phase 1 3
NCT07304154A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesChronic Inflammatory Demyelinating Polyneuropathy
RECRUITING52 Analytics
NCT07038447A Study of KITE-363 in Participants With Refractory Autoimmune DiseasesSystemic Lupus Erythematosus
ENROLLING BY_INVITATION52 Analytics
NCT04989803Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell LymphomaRelapsed and/or Refractory B-cell Lymphoma
RECRUITING247 Analytics
PHASE1RECRUITING
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Chronic Inflammatory Demyelinating PolyneuropathyUnlock trial analytics
PHASE1ENROLLING BY_INVITATION
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
Systemic Lupus ErythematosusUnlock trial analytics
PHASE1RECRUITING
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Relapsed and/or Refractory B-cell LymphomaUnlock trial analytics
Study Endpoints
Primary Endpoints
Phase 1a: Percentage of Participants Experiencing Treatment-emergent Adverse Event (TEAEs)
Up to 2 years
Phase 1a: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363
Up to 28 days
Phase 1b: (All Cohorts) Percentage of Participants Experiencing TEAEs
Up to 2 years
Phase 1b: Relapsing Forms of MS (RRMS) and (aSPMS): Number of New T1 Gadolinium Enhancing (GadE+) Lesions on Magnetic Resonance Imaging (MRI) at Week 12
Week 12

This will be reported in participants with relapsing forms of Multiple Sclerosis MS (RRMS) and (aSPMS).

Phase 1b: Relapsing Forms of MS (RRMS and aSPMS): Number of New and/or Enlarging T2 Lesions on MRI at Week 12
Week 12
Phase 1b: Progressive Forms of MS (PPMS) and (naSPMS): Time to Onset of Confirmed Disability Progression Over 12 Weeks (CDP-12)
Up to 2 years
Phase 1b: Myasthenia Gravis (MG): Proportion of Participants of MG Activities of Daily Living (MG-ADL) Responders
Up to Week 24

The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.

Phase 1b: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Proportion of Participants with Confirmed Evidence of Clinical Improvement at Week 24
Week 24

Clinical improvement will be analyzed using inflammatory neuropathy cause and treatment (INCAT) scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate clinical improvement.

Phase 1a: Percentage of Participants Experiencing Adverse Events Defined as Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363
Up to 2 years
Phase 1b: All Cohorts Percentage of Participants Experiencing Treatment-emergent Adverse Event (TEAEs)
Up to 2 years
Phase 1b: Systemic lupus erythematosus (SLE): Proportion of participants meeting DORIS remission and Lupus low Disease Activity State (LLDAS) criteria at Month 6
Month 6
Phase 1b: Lupus Nephritis (LN): Proportion of Participants Meeting DORIS Remission
Month 6
Phase 1b: LN: Proportion of Participants Achieving a Complete Renal Response at Month 6
Month 6
Phase 1b: Systemic Sclerosis (SSc) Cohort: Proportion of Participants With Improvement in Disease Activity by the Revised Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (rCRISS) at Month 6
Month 6
Phase 1b: Idiopathic Inflammatory Myopathy (IIM): Proportions of Participants Meeting European League Against Rheumatism (EULAR)-American College of Rheumatology (ACR) Moderate and Major response 2016 Criteria in Total Improvement Score (TIS) at Month 6
Month 6
Phase 1a: Percentage of Participants Experiencing Adverse Events Defined as Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363 or KITE-753
Up to 28 days

DLTs are defined as the KITE-363-related or KITE-753-related events with onset within the first 28 days after the infusion of KITE-363 or KITE-753 respectively.

Phase 1b: Objective Response Rate (ORR) for KITE-363 and KITE-753 as per investigator's assessment.
Up to 15 years

ORR is defined as the percentage of participants with a complete response (CR) or a partial response (PR) by the International Working Group (IWG) Lugano Response Criteria for Malignant Lymphoma (Cheson 2014) as determined by investigator assessment.

Phase 2: ORR as per central assessment for KITE-753
Up to 15 years
Secondary Endpoints
Relapsing forms of MS (RRMS and aSPMS): Annual Relapse Rate
Up to 2 years
Relapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-12
Up to 2 years
Relapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-24
Up to 2 years
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Phase 1a: KITE-363 (Dose Escalation)EXPERIMENTALParticipants with relapsing forms of multiple sclerosis (RMS), progressive forms of multiple sclerosis (PMS), myasthenia gravis (MG), and/or chronic inflammatory demyelinating polyneuropathy (CIDP) will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by infusion of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells at a single dose level, with different participants receiving sequential dose-escalation levels to find the Phase 1b recommended dose.
Phase 1b: KITE-363 (Dose Expansion)EXPERIMENTALParticipants with RMS, PMS, MG, and/or CIDP will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed Phase 1a recommended dose of KITE-363 CAR T cells.
Phase 1 a/b: KITE-363EXPERIMENTALPhase 1a (Dose escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-363. Phase 1b (Dose expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-363 at 1 or more dose-level deemed to be tolerable. \[Recruitment completed for this arm\]
Phase 1 a/b: KITE-753EXPERIMENTALPhase 1a (Dose escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-753 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-753. Phase 1b (Dose expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-753 at 1 or more dose-level deemed to be tolerable. \[Recruitment open for frontline LBCL and r/r MCL for this arm\]
Phase 2: KITE-753EXPERIMENTALParticipants with r/r large B-cell lymphoma who have received at least 2 prior lines of systemic therapy will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-753 chimeric antigen receptor (CAR) transduced autologous T cells /kg intravenously (IV).
Interventions
NameTypeDescription
KITE-363BIOLOGICALA single infusion of CAR-transduced autologous T cells administered as intravenous infusion.
FludarabineDRUGAdministered intravenously
CyclophosphamideDRUGAdministered intravenously
KITE-753BIOLOGICALA single infusion of CAR-transduced autologous T cells administered intravenously
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites6

Key Inclusion Criteria: * Reproductive status-related eligibility and contraception requirements: * Participants must agree to use protocol-specified method(s) of contraception where applicable Inclusion Criteria for multiple sclerosis (MS): MS (Relapsing and progressive forms): * Diagnosed w...

Countries:United StatesAustraliaCanadaGermanyNetherlandsUnited Kingdom
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJul 2, 2026NCT07304154lastUpdatePostDate: changed
LOWJul 2, 2026NCT07304154lastUpdatePostDate: changed
LOWJul 2, 2026NCT07304154lastUpdatePostDate: changed
LOWJul 2, 2026NCT07304154lastUpdatePostDate: changed
LOWJun 29, 2026NCT04989803lastUpdatePostDate: changed
LOWJun 29, 2026NCT04989803lastUpdatePostDate: changed
LOWJun 16, 2026NCT07038447lastUpdatePostDate: changed
LOWJun 16, 2026NCT07038447lastUpdatePostDate: changed
LOWJun 16, 2026NCT07038447lastUpdatePostDate: changed
LOWJun 8, 2026NCT07304154lastUpdatePostDate: changed
LOWJun 8, 2026NCT07304154lastUpdatePostDate: changed
LOWJun 8, 2026NCT07304154lastUpdatePostDate: changed
LOWJun 4, 2026NCT04989803lastUpdatePostDate: changed
LOWJun 4, 2026NCT04989803lastUpdatePostDate: changed
LOWJun 4, 2026NCT04989803lastUpdatePostDate: changed
LOWJun 4, 2026NCT04989803lastUpdatePostDate: changed
LOWJun 4, 2026NCT04989803lastUpdatePostDate: changed
LOWMay 26, 2026NCT07304154Status: NOT_YET_RECRUITING → RECRUITING
MEDIUMMay 26, 2026NCT04989803primaryCompletionDate: changed
LOWMay 26, 2026NCT07038447primaryCompletionDate: changed